A Cyclic Peptide Targets Glioblastoma by Binding to Aberrantly Exposed SNAP25

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Tumor-specific molecular changes are crucial for understanding disease mechanisms and developing diagnostic/therapeutic markers.
• Glioblastoma (GBM) remains a challenging brain tumor with a need for improved targeted therapies.

Purpose of the Study:

• To identify and characterize a novel peptide that specifically targets GBM.
• To elucidate the molecular receptor for the identified peptide.
• To evaluate the potential of the peptide and its receptor for GBM diagnosis and drug delivery.

Main Methods:

• Intravenous injection of cyclic peptide CESPLLSEC (CES) in U87MG and WT-GBM models.
• Affinity chromatography to identify CES binding partners in tumor extracts.
• Fluorescent labeling, direct binding assays, and flow cytometry to confirm receptor interaction.
• In vitro photodynamic therapy assays using CES peptide-drug conjugates.
• Surface plasmon resonance and molecular modeling to study receptor-ligand interactions.

Main Results:

• CES peptide specifically accumulated in intracranial GBM models and associated with vasculature.
• Synaptosomal Associated Protein 25 (SNAP25) was identified as the CES receptor.
• CES demonstrated specific binding to SNAP25, which is cell surface-expressed in GBM but not normal tissues.
• CES-drug conjugates exhibited selective cytotoxicity against SNAP25+ GBM cell lines.
• SNAP25 binds to collagen V and collagen VI, with potential competition from CES for binding sites.

Conclusions:

• CES is a promising peptide for targeted drug delivery to glioblastoma.
• SNAP25 is a potential molecular marker for GBM diagnosis and a target for therapy.
• The interaction between CES, SNAP25, and extracellular matrix components warrants further investigation.